Are there any effective interventions to treat symptoms of pityriasis rosea?
Limitations of this review include the small number of trials identified (3), the small number of participants involved, the inadequate methodology of two of the studies, and finding only 1 small study (40 people) that reported the clinical benefits of oral erythromycin. However, the methodological quality of this study was judged to be good.
Pityriasis rosea is a scaly rash that affects mainly young adults. It is relatively common, affecting about 170 out of every 100,000 people in the community each year. About 50 per cent of patients experience moderate to severe itch, but most people recover within 2 to 12 weeks.